<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35392757</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Glomerular endothelial expression of type I IFN-stimulated gene, DExD/H-Box helicase 60 via toll-like receptor 3 signaling: possible involvement in the pathogenesis of lupus nephritis.</ArticleTitle>
        <Pagination>
          <StartPage>137</StartPage>
          <EndPage>145</EndPage>
          <MedlinePgn>137-145</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2027249</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Sustained type I interferon (IFN) activation <i>via</i> Toll-like receptor (TLR) 3, 7 and 9 signaling has been reported to play a pivotal role in the development of lupus nephritis (LN). Although type I IFN activation has been shown to induce interferon-stimulated genes (ISGs) expression in systemic lupus erythematosus, the implication of ISGs expression in intrinsic glomerular cells remains largely unknown.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We treated cultured human glomerular endothelial cells (GECs) with polyinosinic-polycytidylic acid (poly IC), R848, and CpG (TLR3, TLR7, and TLR9 agonists, respectively) and analyzed the expression of DExD/H-Box Helicase 60 (DDX60), a representative ISG, using quantitative reverse transcription-polymerase chain reaction and western blotting. Additionally, RNA interference against IFN-β or DDX60 was performed. Furthermore, cleavage of caspase 9 and poly (ADP-ribose) polymerase (PARP), markers of cells undergoing apoptosis, was examined using western blotting. We conducted an immunofluorescence study to examine endothelial DDX60 expression in biopsy specimens from patients with LN.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We observed that endothelial expression of DDX60 was induced by poly IC but not by R848 or CpG, and RNA interference against IFN-β inhibited poly IC-induced DDX60 expression. DDX60 knockdown induced cleavage of caspase 9 and PARP. Intense endothelial DDX60 expression was observed in biopsy specimens from patients with diffuse proliferative LN.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Glomerular endothelial DDX60 expression may prevent apoptosis, which is involved in the pathogenesis of LN. Modulating the upregulation of the regional innate immune system <i>via</i> TLR3 signaling may be a promising treatment target for LN.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Karasawa</LastName>
            <ForeName>Takao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Riko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imaizumi</LastName>
            <ForeName>Tadaatsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hashimoto</LastName>
            <ForeName>Shun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujita</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aizawa</LastName>
            <ForeName>Tomomi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsugawa</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawaguchi</LastName>
            <ForeName>Shogo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seya</LastName>
            <ForeName>Kazuhiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terui</LastName>
            <ForeName>Kiminori</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of School Health Science, Hirosaki University Faculty of Education, Hirosaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495344">TLR3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>77238-31-4</RegistryNumber>
          <NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="C561888">DDX60 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.13</RegistryNumber>
          <NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O84C90HH2L</RegistryNumber>
          <NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053487" MajorTopicYN="Y">DEAD-box RNA Helicases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051196" MajorTopicYN="Y">Toll-Like Receptor 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DExD/H-Box Helicase 60 (DDX60)</Keyword>
        <Keyword MajorTopicYN="N">Glomerular endothelial cells</Keyword>
        <Keyword MajorTopicYN="N">Poly (ADP-ribose) polymerase (PARP)</Keyword>
        <Keyword MajorTopicYN="N">lupus nephritis</Keyword>
        <Keyword MajorTopicYN="N">toll-like receptor</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35392757</ArticleId>
        <ArticleId IdType="pmc">PMC9004514</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2027249</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hagberg N, Rönnblom L.. 
Systemic lupus erythematosus-a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82(3):199–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26099519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X, Ren Y, He X.. 
IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol. 2021;12:676082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8093624</ArticleId>
            <ArticleId IdType="pubmed">33959133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorenz G, Lech M, Anders HJ.. 
Toll-like receptor activation in the pathogenesis of lupus nephritis. Clin Immunol. 2017;185:86–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27423476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conti F, Spinelli FR, Truglia S, et al. . 
Kidney expression of toll like receptors in lupus nephritis: quantification and clinicopathological correlations. Mediators Inflamm. 2016;2016:7697592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5011205</ArticleId>
            <ArticleId IdType="pubmed">27635115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robson MG.
Toll-like receptors and renal disease. Nephron Exp Nephrol. 2009;113(1):e1–e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19590236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ.
Pseudoviral immunity – a novel concept for lupus. Trends Mol Med. 2009;15(12):553–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19896418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka H, Imaizumi T.. 
Inflammatory chemokine expression via toll-like receptor 3 signaling in normal human mesangial cells. Clin Dev Immunol. 2013;2013:984708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710592</ArticleId>
            <ArticleId IdType="pubmed">23935652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oshiumi H, Mifsud EJ, Daito T.. 
Links between recognition and degradation of cytoplasmic viral RNA in innate immune response. Rev Med Virol. 2016;26(2):90–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26643446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grünvogel O, Esser-Nobis K, Reustle A, et al. . 
DDX60L is an interferon-stimulated gene product restricting hepatitis C virus replication in cell culture. J Virol. 2015;89(20):10548–10568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4580188</ArticleId>
            <ArticleId IdType="pubmed">26269178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu TY, Wu CN, Sie HC, et al. . 
Subsite-specific association of DEAD box RNA helicase DDX60 with the development and prognosis of oral squamous cell carcinoma. Oncotarget. 2016;7(51):85097–85108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5356722</ArticleId>
            <ArticleId IdType="pubmed">27835882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahadat MJ, Bodewes ILA, Maria NI, et al. . 
Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?
Arthritis Res Ther. 2018;20(1):4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5763828</ArticleId>
            <ArticleId IdType="pubmed">29321042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imaizumi T, Tanaka H, Mechti N, et al. . 
Polyinosinic-polycytidylic acid induces the expression of interferon-stimulated gene 20 in mesangial cells. Nephron Exp Nephrol. 2011;119(2):e40–e48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21832855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imaizumi T, Shimada T, Matsumiya T, et al. . 
Interferon-stimulated gene 15, a type I interferon-dependent transcript, is involved in a negative feedback loop in innate immune reactions in human mesangial cells. Nephron. 2016;132(2):144–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26844778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imaizumi T, Yano C, Numata A, et al. . 
Interferon (IFN)-induced protein 35 (IFI35), a type I interferon-dependent transcript, upregulates inflammatory signaling pathways by activating toll-like receptor 3 in human mesangial cells. Kidney Blood Press Res. 2016;41(5):635–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27639618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto S, Imaizumi T, Aizawa T, et al. . 
Expression of IFN-induced transmembrane protein 1 in glomerular endothelial cells. Pediatr Int. 2021;63(9):1075–1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33332692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldani C, Lazzè MC, Bottone MG, et al. . 
Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where?
Exp Cell Res. 2001;269(2):193–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11570811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldani C, Scovassi AI.. 
Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7(4):321–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12101391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Imaizumi T, Kawaguchi S, et al. . 
Toll-like receptor 3 signaling contributes to regional neutrophil recruitment in cultured human glomerular endothelial cells. Nephron. 2018;139(4):349–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29791907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirono K, Imaizumi T, Aizawa T, et al. . 
Endothelial expression of fractalkine (CX3CL1) is induced by toll-like receptor 3 signaling in cultured human glomerular endothelial cells. Mod Rheumatol. 2020;30(6):1074–1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31625434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuravi SJ, McGettrick HM, Satchell SC, et al. . 
Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. J Immunol. 2014;193(1):234–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4067868</ArticleId>
            <ArticleId IdType="pubmed">24872191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai AS, Lai KN.. 
Viral nephropathy. Nat Clin Pract Nephrol. 2006;2(5):254–262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7097026</ArticleId>
            <ArticleId IdType="pubmed">16932438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai T, Akira S.. 
TLR signaling. Cell Death Differ. 2006;13(5):816–825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16410796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hägele H, Allam R, Pawar RD, et al. . 
Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol Dial Transplant. 2009;24(11):3312–3318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19608629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato R, Imaizumi T, Aizawa T, et al. . 
Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells . Ren Fail. 2021;43(1):643–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8032345</ArticleId>
            <ArticleId IdType="pubmed">33820486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SK, Shakya AK, O’Callaghan DJ.. 
Interferon gamma inhibits equine herpesvirus 1 replication in a cell line-dependent manner. Pathogens. 2021;10(4):484–498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8073143</ArticleId>
            <ArticleId IdType="pubmed">33923733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalaaji M, Fenton KA, Mortensen ES, et al. . 
Glomerular apoptotic nucleosomes are Central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007;71(7):664–672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17332738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Chan TM.. 
Anti-dsDNA antibodies and resident renal cells – their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin Immunol. 2017;185:40–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27612436</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
